Sanofi Consumer Healthcare India Ltd on Wednesday reported a strong year-on-year performance for the latest reported quarter, with revenue, operating profit and net profit all posting robust growth, supported by higher sales and improved operating leverage.

The quarter is being reported as Q4 because it represents the final quarter of the company’s reported financial cycle, aligned with its post-demerger reporting structure following the separation from Sanofi India Limited.

Net sales for the quarter came in at ₹251 crore, rising 47% from ₹171 crore in the corresponding period last year. Along with the quarterly results, the board of Sanofi Consumer Healthcare India Limited declared a dividend of ₹75 per equity share.

Expenses rise, but operating performance improves

Total expenditure increased to ₹165.1 crore, up 50.1% from ₹110 crore a year earlier, indicating higher business activity and cost expansion alongside revenue growth.

Despite the rise in costs, the company delivered stronger operating performance.

EBIT stood at ₹86.4 crore, up 41.4% compared with ₹61.1 crore in the year-ago quarter.

Depreciation rose sharply to ₹3.4 crore from ₹1 crore, marking a 240% increase, while finance costs remained negligible at around ₹1 crore, broadly unchanged year on year.

EBITDA growth strong; margins largely stable

EBITDA for the quarter was ₹89.8 crore, registering a 44.6% rise from ₹62.1 crore in the previous year period, indicating solid operational momentum.

The company’s operating profit margin (OPM) stood at 35.78%, compared with 36.38% in the year-ago quarter. While margins softened slightly, they remained at a healthy level, suggesting the company was able to absorb higher costs without major profitability pressure.

Net profit surges over 50%

Net profit for the quarter rose to ₹67 crore, up 50.1% from ₹44 crore in the corresponding period last year, supported by strong revenue growth and improved operating earnings.

The profit expansion slightly outpaced EBIT growth, indicating efficient cost control below the operating line and stable financial charges.

Overall performance reflects strong growth trajectory

The quarterly numbers point to a broad-based improvement in the company’s financial profile, with revenue growth translating effectively into operating and bottom-line expansion.

While expenditure growth slightly outpaced revenue growth, the company maintained strong profitability metrics, with EBITDA growth exceeding 40% and margins remaining above 35%.